Country for PR: United States
Contributor: PR Newswire New York
Wednesday, January 04 2023 - 23:50
Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment
ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire-Asianet/ --

                      Study met all primary endpoints

Alphyn Biologics ( 
), a clinical-stage dermatology company developing first-in-class multi-target 
therapeutics, announced today positive results from the first cohort of its 
Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate 
atopic dermatitis (AD). The trial met all of its primary endpoints, 
highlighting AB-101a's potential to be an effective and safe treatment for AD.

Logo -

The randomized, vehicle-controlled, double-blind trial is evaluating the 
treatment protocol of AB-101a across multiple sites using standard scales for 
assessing AD. The trial, conducted in Australia, enrolled 41 AD patients, and 
treatment was evaluated after four weeks.

"As a physician who treated 15 percent of the patients in the clinical trial, I 
am encouraged by the results with AB-101a," said Dr. Stephen Shumack, Clinical 
Associate Professor Dermatology, University of Sydney, and Principal 
Investigator at St George Dermatology & Skin Cancer Centre. "I look forward to 
future trials and gaining a better understanding of AB-101a's potential 
benefits for patients."

"Patients with mild-to-moderate atopic dermatitis suffer considerably from the 
symptoms of this often debilitating disease, yet available treatments come with 
side effects and safety concerns," said Alphyn CEO Neal Koller. "We are excited 
by these results and look forward to the results of our ongoing cohort treating 
infected AD. We plan to further study AB-101a in a Phase 2b/3 trial this year 
in conjunction with a Series B financing."

Alphyn intends to present the full results of this trial at a scientific 
conference and submit a paper for publication in a peer-reviewed journal. 
Enrollment is ongoing in the second cohort of the Phase 2a clinical trial. This 
cohort is investigating the unique ability of AB-101a to treat the infected 
component of AD in AD patients who are suffering from bacterial infections, 
including Staphylococcus aureus, or "Staph," and MRSA, the antibiotic-resistant 
Staph. Alphyn anticipates AB-101a will be effective in treating non-infected AD 
and infected AD. AB-101a should provide AD patients and physicians a 
comprehensive, safe, and convenient treatment option.

AB-101a was developed using Alphyn's proprietary AB-101 platform. The platform 
has multiple bioactive compounds and, therefore, multiple mechanisms of action 
to address multiple problems of any target disease. Alphyn was able to begin 
the AB-101a clinical trial program in Phase 2 due to the strong safety profile 
of its AB-101 platform.

Alphyn Biologics is a clinical-stage dermatology company developing 
first-in-class multi-target therapeutics for severe and prevalent skin diseases 
based on its AB-101 platform. Its lead product candidate, AB-101a, is being 
developed as a topical treatment for atopic dermatitis (AD), the most common 
form of eczema. AB-101a has demonstrated a strong safety profile and is in 
development to uniquely target AD's immune system and bacterial components, 
making it ideal for treating AD and infected AD. Alphyn's AB-101 platform has 
multiple bioactive compounds and therefore multiple mechanisms of action to 
support a robust pipeline of dermatologic therapeutics that have potential 
safety, efficacy and regulatory marketing authorization advantages. Alphyn is 
based in Annapolis, Maryland and Cincinnati, Ohio, and has a wholly owned 
Australia subsidiary. The company became operational in 2020 and has raised 
approximately $6.9 million.
SOURCE  Alphyn Biologics

CONTACT: Corporate: Neal Koller,, (410) 690-8687; 
Media: Susan Thomas,, (619) 540-9195